Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
18 03 2021
Historique:
received: 12 01 2021
revised: 10 03 2021
accepted: 12 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 25 2 2023
Statut: epublish

Résumé

Diffuse large B-cell lymphoma (DLBCL) is the commonest form of lymphoid malignancy, with a prevalence of about 40% worldwide. Its classification encompasses a common form, also termed as "not otherwise specified" (NOS), and a series of variants, which are rare and at least in part related to viral agents. Over the last two decades, DLBCL-NOS, which accounts for more than 80% of the neoplasms included in the DLBCL chapter, has been the object of an increasing number of molecular studies which have led to the identification of prognostic/predictive factors that are increasingly entering daily practice. In this review, the main achievements obtained by gene expression profiling (with respect to both neoplastic cells and the microenvironment) and next-generation sequencing will be discussed and compared. Only the amalgamation of molecular attributes will lead to the achievement of the long-term goal of using tailored therapies and possibly chemotherapy-free protocols capable of curing most (if not all) patients with minimal or no toxic effects.

Identifiants

pubmed: 33803671
pii: cells10030675
doi: 10.3390/cells10030675
pmc: PMC8003012
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 21198

Références

Haematologica. 2020 Aug;105(8):e432-e436
pubmed: 32467139
Blood. 2003 Jan 1;101(1):78-84
pubmed: 12393466
Haematologica. 2017 Oct;102(10):e404-e406
pubmed: 28679653
Leukemia. 2020 Feb;34(2):543-552
pubmed: 31530861
N Engl J Med. 2008 Nov 27;359(22):2313-23
pubmed: 19038878
Lancet Oncol. 2019 May;20(5):649-662
pubmed: 30948276
Ann Oncol. 2018 Dec 1;29(12):2363-2370
pubmed: 30307529
Cancer Discov. 2019 Apr;9(4):546-563
pubmed: 30705065
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
J Clin Oncol. 2019 Jan 20;37(3):202-212
pubmed: 30523719
Blood. 1994 Sep 1;84(5):1361-92
pubmed: 8068936
Cancer Biol Med. 2017 May;14(2):151-161
pubmed: 28607806
Blood. 2018 Nov 29;132(22):2401-2405
pubmed: 30257882
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
N Engl J Med. 2002 Jun 20;346(25):1937-47
pubmed: 12075054
J Clin Oncol. 2007 Mar 1;25(7):805-12
pubmed: 17327602
Blood. 2013 May 16;121(20):4021-31; quiz 4250
pubmed: 23449635
Blood. 2012 Nov 8;120(19):3986-96
pubmed: 22955915
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Blood Cancer J. 2021 Jan 7;11(1):9
pubmed: 33414443
J Clin Oncol. 2012 Oct 1;30(28):3460-7
pubmed: 22665537
iScience. 2020 Sep 16;23(10):101562
pubmed: 33083730
Cancer Cell. 2020 Apr 13;37(4):551-568.e14
pubmed: 32289277
Blood. 2020 May 14;135(20):1759-1771
pubmed: 32187361
Blood. 2014 Feb 20;123(8):1214-7
pubmed: 24398326
Sci Transl Med. 2016 Nov 9;8(364):364ra155
pubmed: 27831904
Leukemia. 2012 Sep;26(9):2103-13
pubmed: 22437443
Clin Cancer Res. 2009 Sep 1;15(17):5494-502
pubmed: 19706817
J Clin Oncol. 2011 Jan 10;29(2):200-7
pubmed: 21135273
Nat Med. 2020 Apr;26(4):577-588
pubmed: 32094924
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6
pubmed: 12900505
J Clin Oncol. 2017 Aug 1;35(22):2515-2526
pubmed: 28525305
Blood. 2011 May 5;117(18):4836-43
pubmed: 21441466
J Clin Oncol. 2015 Sep 10;33(26):2848-56
pubmed: 26240231
Haematologica. 2020 Aug 13;:
pubmed: 32817282
Mod Pathol. 2009 Aug;22(8):1094-101
pubmed: 19448593
Cell. 2017 Oct 5;171(2):481-494.e15
pubmed: 28985567
J Pathol. 2006 Apr;208(5):714-23
pubmed: 16400625
Blood. 2017 Apr 6;129(14):1947-1957
pubmed: 28096087
Cancer Discov. 2021 Feb 4;:
pubmed: 33541860
Br J Haematol. 2018 Apr;181(2):272-275
pubmed: 28198001
Am J Hematol. 2013 Apr;88(4):273-6
pubmed: 23460351
J Clin Oncol. 2019 Jan 20;37(3):175-177
pubmed: 30523718
Blood. 2007 Apr 1;109(7):2700-7
pubmed: 17119127
Cell. 2019 Jul 25;178(3):699-713.e19
pubmed: 31280963
Blood. 2020 May 14;135(20):1722-1724
pubmed: 32407529
N Engl J Med. 1993 Apr 8;328(14):1002-6
pubmed: 7680764
N Engl J Med. 2021 Mar 4;384(9):842-858
pubmed: 33657296
Haematologica. 2005 Mar;90(3):341-7
pubmed: 15749666
J Clin Oncol. 2019 Jan 20;37(3):190-201
pubmed: 30523716
Am J Clin Pathol. 2011 Jan;135(1):54-61
pubmed: 21173124
Blood. 2011 Aug 4;118(5):1350-8
pubmed: 21670469
Haematologica. 2019 Nov 14;105(9):2298-2307
pubmed: 33054054
Haematologica. 2020 Feb 13;105(11):2667-2670
pubmed: 33131258
J Clin Oncol. 2017 Nov 1;35(31):3529-3537
pubmed: 28796588
Blood. 2004 Jan 1;103(1):275-82
pubmed: 14504078
Leuk Lymphoma. 2014 Feb;55(2):415-24
pubmed: 23697845

Auteurs

Stefano A Pileri (SA)

Division of Haematopathology, European Institute of Oncology, IEO IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Claudio Tripodo (C)

Tumor Immunology Unit, University of Palermo, 90133 Palermo, Italy.
Tumor and Microenvironment Histopathology Unit, IFOM, the FIRC Institute of Molecular Oncology, 20139 Milan, Italy.

Federica Melle (F)

Division of Haematopathology, European Institute of Oncology, IEO IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Giovanna Motta (G)

Division of Haematopathology, European Institute of Oncology, IEO IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Valentina Tabanelli (V)

Division of Haematopathology, European Institute of Oncology, IEO IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Stefano Fiori (S)

Division of Haematopathology, European Institute of Oncology, IEO IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Maria Carmela Vegliante (MC)

Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Viale Flacco 65, 70124 Bari, Italy.

Saveria Mazzara (S)

Division of Haematopathology, European Institute of Oncology, IEO IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Sabino Ciavarella (S)

Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Viale Flacco 65, 70124 Bari, Italy.

Enrico Derenzini (E)

Division of Haemato-Oncology, European Institute of Oncology, IEO IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Department of Health Sciences, University of Milan, Via di Rudinì 8, 20146 Milan, Italy.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH